Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.

Publication date: Jun 08, 2019

STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti-JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year interim analysis was to determine the effectiveness of natalizumab in establishing and maintaining no evidence of disease activity (NEDA) in early RRMS.

Patients aged 18-65 years had an RRMS diagnosis

Open Access PDF

Perumal, J., Fox, R.J., Balabanov, R., Balcer, L.J., Galetta, S., Makh, S., Santra, S., Hotermans, C., and Lee, L. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. 18276. 2019 BMC Neurol (19):1.

Concepts Keywords
BMC Relapsing–remitting
JC Virus Medicine
Multiple Sclerosis Natalizumab
Natalizumab Immunosuppressants
Seronegative Immunology
Monoclonal antibodies
Medical specialties
Multiple sclerosis
Multiple sclerosis
Autoimmune diseases

Semantics

Type Source Name
gene UNIPROT FURIN
gene UNIPROT ZBTB8OS
drug DRUGBANK Ribostamycin
gene UNIPROT RNMT
gene UNIPROT MET
gene UNIPROT SLTM
drug DRUGBANK Methionine
gene UNIPROT F11R
disease MESH cognitive impairment
gene UNIPROT PFDN1
gene UNIPROT PDF
gene UNIPROT GDF15
drug DRUGBANK Fenamole
gene UNIPROT INTU
disease MESH Mult
gene UNIPROT COL9A3
gene UNIPROT COMP
gene UNIPROT COL9A1
gene UNIPROT COL9A2
gene UNIPROT SCN8A
gene UNIPROT EXOG
disease MESH sclerosis
gene UNIPROT TNFSF13
gene UNIPROT ANP32B
drug DRUGBANK Antithymocyte immunoglobulin (rabbit)
drug DRUGBANK Coenzyme M
gene UNIPROT PDC
gene UNIPROT GTF2IRD1
gene UNIPROT OXCT2
gene UNIPROT MARK1
drug DRUGBANK Etodolac
gene UNIPROT THOP1
disease MESH Progressive multifocal leukoencephalopathy
drug DRUGBANK Fingolimod
drug DRUGBANK Glatiramer
gene UNIPROT GLA
gene UNIPROT NAT8
drug DRUGBANK Gamolenic acid
gene UNIPROT TNF
disease MESH dif
disease MESH anaphylactic reaction
disease MESH emergency
disease MESH subdural hematoma
disease MESH palsy
disease DOID colitis
disease MESH colitis
gene UNIPROT HMBS
gene UNIPROT BTG3
gene UNIPROT TPO
gene UNIPROT MLIP
gene UNIPROT AK6
gene UNIPROT ATM
gene UNIPROT SLC33A1
gene UNIPROT AGTR1
gene UNIPROT TNFRSF11A
gene UNIPROT HNRNPA1
gene UNIPROT COX5A
gene UNIPROT COX8A
gene UNIPROT CPOX
gene UNIPROT FRZB
disease MESH tics
gene UNIPROT DEPP1
gene UNIPROT GOPC
gene UNIPROT LARGE1
gene UNIPROT PLXNA2
gene UNIPROT MEA1
drug DRUGBANK Cysteamine
gene UNIPROT MENT
drug DRUGBANK Trestolone
disease MESH Multiple
gene UNIPROT ARSA
gene UNIPROT CYREN
drug DRUGBANK Acetylsalicylic acid
drug DRUGBANK Rituximab
drug DRUGBANK Cladribine
drug DRUGBANK Mycophenolic acid
drug DRUGBANK Azathioprine
drug DRUGBANK Mitoxantrone
disease MESH SD1
gene UNIPROT EHD1
gene UNIPROT DMTN
gene UNIPROT MAX
disease MESH Death
disease MESH visual
gene UNIPROT MALL
disease MESH infection
gene UNIPROT PML
disease DOID PML
disease MESH leukoencephalopathy
gene UNIPROT SLC35G1
disease DOID Multiple Sclerosis
disease MESH Multiple Sclerosis
drug DRUGBANK Gadolinium
disease MESH relapses
gene UNIPROT RBFOX2
gene UNIPROT ARMC9
gene UNIPROT AKR1A1
disease MESH diagnosis
disease DOID relapsing-remitting multiple sclerosis
disease MESH relapsing-remitting multiple sclerosis
drug DRUGBANK Natalizumab

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *